Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?
about
Indications to Hospital Admission and Isolation of Children With Possible or Defined Tuberculosis: Systematic Review and Proposed Recommendations for Pediatric Patients Living in Developed Countries. [Corrected]Prevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesAntibiotic preferences for childhood pneumonia vary by physician type and European regionPerformance of lung ultrasonography in children with community-acquired pneumonia.Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines.Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumoniaCommunity-acquired lobar pneumonia in children in the era of universal 7-valent pneumococcal vaccination: a review of clinical presentations and antimicrobial treatment from a Canadian pediatric hospital.Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia.Influenza C virus–associated community-acquired pneumonia in children.Assessment of Treatment of Community Acquired Severe Pneumonia by Two Different AntibioticsAssociation between radiological findings and severity of community-acquired pneumonia in children.Assessment of the Usefulness of Multiplex Real-Time PCR Tests in the Diagnostic and Therapeutic Process of Pneumonia in Hospitalized Children: A Single-Center Experience.Oral penicillin prescribing for children in the UK: a comparison with BNF for Children age-band recommendations.Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection.Pharmacotherapy for pneumococcal infections: an update.Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.Community-acquired Pneumonia and its Complications.The role of the NxTAG® respiratory pathogen panel assay and other multiplex platforms in clinical practice.Biomarkers in Pediatric Community-Acquired Pneumonia.Impact of rhinovirus nasopharyngeal viral load and viremia on severity of respiratory infections in children.Variation in paediatric hospital antibiotic guidelines in Europe.Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.[Lung diseases in children].International guidelines on tackling community-acquired pneumonia show major discrepancies between developed and developing countries.Lung ultrasonography to diagnose community-acquired pneumonia in children.Monitoring adherence to guidelines of antibiotic use in pediatric pneumonia: the MAREA study.Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review
P2860
Q26774770-6B0AEA51-3AB0-4D89-B382-5A696CE17595Q28077703-0166257E-5C4B-4A0E-B5F5-D6BBB5250419Q28596679-55E56958-1519-47E6-AC2F-2F9AE6CA0605Q33575904-C53A7C66-F350-4F37-B3FD-A7A35A4E802DQ33792393-C480973D-0A29-4D37-9E9A-B67BB31F7EC7Q34152719-D2578BA1-1176-4115-BC8A-8B1B3E1BABD1Q34396310-E71883AB-8AA6-47B4-A6F3-88A583C979F3Q36083137-FF474F7A-B6BF-402A-A3A7-FDEA75EE9486Q36251685-51A2432A-C575-4A07-8A8A-1E319AC5AF03Q37102878-3F28E20D-6E47-4151-86EA-5ED80342D89FQ37357303-AB3B5CFD-3CF4-458E-8628-A6685E6EB22FQ37611299-0DEB63CE-10ED-4717-9A1B-8AF7CD8A5418Q37660847-6D2AD497-CF5C-4E1E-B94B-F9DA1A0E15DBQ38061407-C70A1C0B-18D1-4DFC-B72D-E9E898F21BE0Q38068919-409DCBCA-6CC1-449A-B082-5F259BCDA36CQ38170557-AFEFECBA-B645-40B8-9D7F-5D43139BBB98Q38481640-DF37B177-B247-4301-8E12-ED5B5F084AB0Q38789297-18753B1B-C56E-4D3D-9BA7-D45A6DEB821BQ39144356-3BDEF26E-AE36-4D60-82C2-1364D2E015F0Q40239969-54C4C7AF-A991-448B-A44A-310E3B4DB809Q40488754-12468F50-4FBE-44A5-BAEF-CB91EE70F3B0Q41001680-4844F49B-0124-412E-966B-1577E93DE08CQ41196429-B5F223D8-B2F5-4AEC-AD04-D24E168F6D03Q44318176-7033CC31-E8BA-41ED-8A0E-6D4E6135F075Q47131420-6DEEABE8-4027-4B25-86F4-993142834268Q47155877-D1A8F389-1851-4CA9-9097-470A41CD54A1Q57923301-472DEE22-4684-44C3-B927-37E7CD4FF20D
P2860
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@en
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@nl
type
label
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@en
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@nl
prefLabel
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@en
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@nl
P2093
P50
P1476
Antibiotic therapy for pediatr ...... hat and for how long to treat?
@en
P2093
Anne Vergison
David Greenberg
Fernanda Rodrigues
George A Syrogiannopoulos
Javier Diez Domingo
Markus Knuf
Oana Falup Pecurariu
Robert Cohen
Ulrich Heininger
Urs B Schaad
P304
P356
10.1097/INF.0B013E318255DC5B
P577
2012-06-01T00:00:00Z